Compare Fresenius Kabi Onco. with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs TORRENT PHARMA - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. TORRENT PHARMA FRESENIUS KABI ONCO./
TORRENT PHARMA
 
P/E (TTM) x 22.1 53.8 41.2% View Chart
P/BV x 3.1 6.4 48.3% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 FRESENIUS KABI ONCO.   TORRENT PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
TORRENT PHARMA
Mar-18
FRESENIUS KABI ONCO./
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1761,550 11.4%   
Low Rs791,144 6.9%   
Sales per share (Unadj.) Rs37.7354.7 10.6%  
Earnings per share (Unadj.) Rs5.140.1 12.7%  
Cash flow per share (Unadj.) Rs6.764.2 10.5%  
Dividends per share (Unadj.) Rs014.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs42.5273.1 15.6%  
Shares outstanding (eoy) m158.23169.22 93.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.43.8 88.9%   
Avg P/E ratio x25.033.6 74.3%  
P/CF ratio (eoy) x18.921.0 90.3%  
Price / Book Value ratio x3.04.9 60.7%  
Dividend payout %034.9 0.0%   
Avg Mkt Cap Rs m20,135227,897 8.8%   
No. of employees `0001.214.7 7.8%   
Total wages/salary Rs m70311,353 6.2%   
Avg. sales/employee Rs Th5,176.24,083.0 126.8%   
Avg. wages/employee Rs Th610.4772.3 79.0%   
Avg. net profit/employee Rs Th699.6461.3 151.6%   
INCOME DATA
Net Sales Rs m5,96360,021 9.9%  
Other income Rs m182,988 0.6%   
Total revenues Rs m5,98163,009 9.5%   
Gross profit Rs m1,43013,493 10.6%  
Depreciation Rs m2584,086 6.3%   
Interest Rs m-263,085 -0.8%   
Profit before tax Rs m1,2169,310 13.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3422,529 13.5%   
Profit after tax Rs m8066,781 11.9%  
Gross profit margin %24.022.5 106.7%  
Effective tax rate %28.127.2 103.6%   
Net profit margin %13.511.3 119.6%  
BALANCE SHEET DATA
Current assets Rs m5,10252,623 9.7%   
Current liabilities Rs m2,38552,022 4.6%   
Net working cap to sales %45.61.0 4,545.3%  
Current ratio x2.11.0 211.4%  
Inventory Days Days150120 125.5%  
Debtors Days Days11376 148.6%  
Net fixed assets Rs m5,14885,016 6.1%   
Share capital Rs m158846 18.7%   
"Free" reserves Rs m6,55645,376 14.4%   
Net worth Rs m6,73246,222 14.6%   
Long term debt Rs m95241,115 2.3%   
Total assets Rs m10,388142,432 7.3%  
Interest coverage x-45.84.0 -1,139.3%   
Debt to equity ratio x0.10.9 15.9%  
Sales to assets ratio x0.60.4 136.2%   
Return on assets %7.56.9 108.4%  
Return on equity %12.014.7 81.6%  
Return on capital %14.614.2 102.9%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,29814,580 36.3%   
Fx outflow Rs m1,7723,600 49.2%   
Net fx Rs m3,52510,980 32.1%   
CASH FLOW
From Operations Rs m1,2748,942 14.2%  
From Investments Rs m-1,204-47,070 2.6%  
From Financial Activity Rs m-19634,174 -0.6%  
Net Cashflow Rs m-126-3,655 3.5%  

Share Holding

Indian Promoters % 0.0 71.5 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 7.0 4.3%  
FIIs % 9.6 12.6 76.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 8.8 103.4%  
Shareholders   42,599 26,511 160.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   PROCTER & GAMBLE HEALTH  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Momentum; Sensex Trades 186 Points Higher(12:30 pm)

Share markets in India are presently trading on a strong note. Sectoral indices are trading on a mixed note with stocks in the telecom sector.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS